Advanced Micro Devices (AMD) offers a compelling long-term investment with its growing market share in semiconductors and a strategic push into AI infrastructure. With a 20% upside potential, a price...
Toast, Inc. (TOST) is making waves in the restaurant technology sector, offering a lucrative investment opportunity amidst evolving consumer demands. With a robust growth trajectory and a target price of...
Dive into the semiconductor sector to uncover potentially undervalued opportunities among 20 key players, including giants like Taiwan Semiconductor and ASML, and niche innovators such as Impinj and Aehr Test...
Discover why Taiwan Semiconductor Manufacturing Company (TSM) is a hot “Buy” with a 12-month target of $135. As the titan of the semiconductor foundry world, TSMC is perfectly positioned to...
In the dynamic realm of biopharma, Vertex Pharmaceuticals holds a commanding position in cystic fibrosis treatment, boasting a market capitalisation over $100 billion. With patent protection on key therapies until...
In the tumultuous biotech sector, Moderna emerges as an intriguing contrarian bet with its mRNA platform holding untapped potential. Despite political headwinds and market scepticism, the company's diverse pipeline, including...
A biotech titan, renowned for its mRNA innovation, might just be undervalued at a price nearly equivalent to its cash reserves. With $2 billion in COVID-19 vaccine revenues and over...
The biotech sector is in turmoil after the nomination of a controversial U.S. health official, raising fears of disrupted vaccine development and regulatory changes. Share prices for companies like Moderna...
In the evolving landscape of biotech regulation, whispers of change at the FDA signal a potential renaissance. Recent leadership shifts hint at a more innovation-friendly approach, potentially expediting approvals for...
Vertex Pharmaceuticals is quietly establishing itself as a powerhouse, generating over $10 billion in annual revenue. With trailblazing innovations like the CRISPR-based Casgevy and non-opioid Journavx, Vertex is reshaping the...
